Ricin-resistant human T-cell hybridomas producing interferon gamma. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Ricin-resistant human T-cell hybridomas producing interferon gamma.

J Immunol Methods. 1985 Mar 18;77(2):207-18. Unique Identifier : AIDSLINE MED/85159089
Crane IJ; Leung H; Parti S; Meager A

Abstract: Ricin-resistant variants of the SH9 T-cell line were selected after growth of this line in medium containing toxic amounts of ricin, a lectin derived from Ricinus communis. The ricin-resistant SH9 lines, SH9.R0 and SH9.R1, were demonstrated to be deficient in cell surface ricin-binding sites, but otherwise had the cellular phenotype of SH9 cells. Ricin-resistant T-cell hybridomas were prepared by fusion of SH9.R0 and SH9.R1 with activated T-lymphocytes. The presence of ricin in the selection medium rapidly killed unfused T-lymphocytes and prevented cell transformation by human T-cell leukaemia virus type 1 (HTLV-1) which is shed by the SH9.R0 and SH9.R1 cells. This ensured that the cells growing out were indeed hybridomas. Ricin-resistant T-cell hybridomas were characterised and also shown to lack cell surface receptors for ricin. Analysis of T-cell surface markers indicated that the T-cell hybridomas could be the result of fusions between SH9.R1 cells and T-helper lymphocytes or T-suppressor lymphocytes. All of the T-cell hybridomas prepared in this study spontaneously produced interferon gamma (IFN gamma).
Keywords: Cell Line Drug Resistance Human Hybridomas Interferon Type II/*BIOSYNTHESIS Ricin/PHARMACOLOGY Support, Non-U.S. Gov't T-Lymphocytes/*IMMUNOLOGY JOURNAL ARTICLE

KWDcelllinedrugresistancehumanhybridomasinterferontypeii/KWDbiosynthesisricin/pharmacologysupport,non-uKWDsKWDgov'tt-lymphocytes/KWDimmunologyjournalarticle
850730
M8570083

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .